QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quidel stock has rallied 75% since late March (vs. about 53% for the S&P 500) to its current level near $154.

Quidel Stock Looks Attractive After A Healthy Correction

OPKO Health

Vaxart

Competition from heavy hitters spooked investors.

Why These 3 Coronavirus-Related Stocks Plummeted More Than 35% in August

Quest Diagnostics

Hologic

These three stocks have consolidated their strong competitive positions in recent months.

3 Lucrative Coronavirus Testing Stocks to Buy Right Now

Avis Budget Group

SmileDirectClub

Baker Hughes Co

BioMarin Pharmaceutical

Invesco

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys Last Week: Avis Budget, SmileDirectClub And More

The Pac-12 is banking on a rapid coronavirus testing platform with Quidel will clear the way for fall sports to begin sooner than 2021.

Pac-12 has 'high degree of confidence' sports will return with new rapid virus testing contract

Quidel: Bad News Is Sometimes No News At All

Abbott Labs

Becton, Dickinson and Co.

With more competition for rapid antigen tests on the way, is Quidel or Becton, Dickinson a better buy?

Competition in the Coronavirus Rapid Test Market: What Does it Mean for Quidel and Becton, Dickinson?

Ulta Beauty

Walmart

Walmart, Abbott Labs, Ulta Beauty and Quidel were our top stock trades for Friday. So, here's what the charts are trying to tell us now.

4 Top Stock Trades for Friday: WMT, ULTA, ABT, QDEL

Co-Diagnostics

GenMark Diagnostics

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Rival Abbott is looking to become the dominant player in the coronavirus test arena.

Here's Why Quidel, Hologic, and Quest Diagnostics Shares Fell Today

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today the following business update in advance of today’s presentation and investor meetings at the 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour. Quidel Corporation, an industry leader in the introduction of FDA-authorized rapid tests for a wide range of diseases and medical

Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour today, Thursday, August 27, 2020. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present today at 3:00 p.m.

Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour

Logitech

PayPal

Each of these stocks is up more than 50% this year and should prove resilient in another crash.

3 Stocks to Buy Ahead of a Potential Second Wave of Coronavirus

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has completed its investigation regarding a report of discordant results (False Positives) at a testing location in Vermont, and found no testing site- or product-related issues with the Sofia® 2 instrument or the Sofia® SARS Antigen FIA. Quidel received a complaint in Vermont rega

Quidel Concludes Sofia® SARS Antigen Investigation From Vermont

Apple

Etsy

Generac Holdings

Barrick Gold

QIAGEN

Boston Beer Company

A handful of corporate giants (market capital > $10 billion) have skyrocketed this year, braving the pandemic and its impact on businesses.

7 Top-Ranked Corporate Giants With More Than 50% Return YTD

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for Quidel’s Emergency Use Authorization (EUA) for the Sofia® SARS Antigen FIA has been amended to include either nasal or nasopharyngeal swabs. The new kit labeling, with the addition of a nasopharyngeal swab, allows Quidel to offer a second kit configuration to support the naso

Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs

Quidel is a high growth in vitro diagnostics company which is continuously developing new products.

Quidel: An Impressive Growth Story For The Long Term

SAN DIEGO--(BUSINESS WIRE)-- #Infectiousdisease--The number of Americans afflicted with Lyme disease was found to be 10 times greater than the 30,000 cases reported each year by the CDC.

National Study Finds Lyme Disease 10 Times Greater Than Reported to CDC; Quidel-Sponsored Webinar Reveals Prevalence and Patterns of Lyme Disease

As of late, it has definitely been a great time to be an investor in Quidel.

Quidel's Shares March Higher, Can It Continue?

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Health Canada authorization to market and sell the Lyra® Direct SARS-CoV-2 Assay in Canada. (IO315563, COVID-19 Medical Device Authorization for Importation or Sale; 07/20/2020) The Lyra® reagents include unique features that provide for simple transport and storage, i

Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization

Despite a stellar 2.6x rise since the March 23 lows of this year, at the current price of around $230 per share we believe Quidel, best known for its diagnostic healthcare products, looks attractive and it has more room for growth.

Despite A 3x Move Quidel Stock Can Gain More

SAN DIEGO--(BUSINESS WIRE)-- #lymedisease--Lyme disease afflicts as many as 400,000 Americans every year and can lead to a number of serious, life-threatening problems if not caught early.

It’s Lyme Disease Season: ‘Be on Guard and Get Tested’ Says Leading Health Solutions Developer Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that the State of Maryland has allowed point-of-care testing for COVID-19. The Maryland Department of Health has allowed point-of-care testing for COVID-19, stating: “Any healthcare provider or healthcare facility, subject to certain terms and conditions, may perform COVID-19 point-of-care (POC) tes

State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program

Teradyne

Trex

These fast movers are currently witnessing a short-term pullback in price. So make sure you're making the most of this opportunity.

News for QuidelOrtho Corp Stock (QDEL)